Expression of E-Cadherin and N-Cadherin in the Endocervix As a Predictive Factor in Patients with Endometrial Cancer
Overview
Chemistry
Molecular Biology
Affiliations
Endometrial cancer (EC) is the most common gynecological malignancy. This study aimed to evaluate the expression of E-cadherin and N-cadherin in primary endometrial lesions and the endocervix in patients with EC to identify noninvasive predictive factors. In this single-center retrospective study, data on 101 patients who underwent surgery for EC were collected. The immunohistochemical expression of E-cadherin and N-cadherin was assessed depending on the tumor grade, location, and cell differentiation. Correlations between E-cadherin and N-cadherin levels in the endocervix and the primary tumor were determined. The degree of histological tumor differentiation significantly affected E-cadherin expression ( = 0.04) but had no impact on N-cadherin levels. In type II EC, the expression of both cadherins in the tumor tissue differed from their endocervical levels. The expression of E-cadherin differed significantly between the endocervix ( < 0.001) and the tumor ( = 0.001), depending on the type of EC. The expression of E-cadherin was related to the N-cadherin level only in the endocervix in patients with type II EC ( = 0.02). E-cadherin and N-cadherin were expressed in the endocervix in patients with EC. The expression of cadherins, determined during cervical cytology, may be a valuable clinical marker of EC.
CD73 restrains mutant β-catenin oncogenic activity in endometrial carcinomas.
Hirsch R, Premsankar S, Kurnit K, Chiou L, Rabjohns E, Lee H bioRxiv. 2024; .
PMID: 39605508 PMC: 11601622. DOI: 10.1101/2024.11.18.624183.